The vascular stents market is anticipated to grow from USD 11.4 billion in 2024 to USD 15.6 billion by 2029, with a CAGR of 6.5%. This growth ...

Key players include Medtronic, Abbott, Boston Scientific ... Product Segment Analysis The market is also divided by product ...

Few medical technologies have faced as many challenges and achieved as much success as transcatheter aortic valve ...

[24] Final results from studies examining the application of the Yukon® (sirolimus) and XIENCE® (everolimus) stents in patients with peripheral arterial disease are also awaited. The Yukon study ...

Among patients undergoing non-cardiac surgery more than 1 year after coronary drug-eluting stent (DES ... examinations of treatment options for peripheral artery disease (PAD), including ...

Carillon Eagle Growth & Income Fund highlighted stocks like Medtronic plc (NYSE:MDT), in the second quarter 2024 investor letter. Medtronic plc (NYSE:MDT) develops, manufactures, and distributes ...

Elixir was comparing its implant against Medtronic’s Resolute Onyx zotarolimus, a stent that releases the immunosuppressant drug zotarolimus. After 12 months, the DynamX bioadaptor, which instead ...

New guidance for clinicians for the evaluation and management of patients with lower extremity peripheral artery disease (LE PAD) was published in May. The 2024 ACC/AHA guideline for LE PAD, the first ...

The FDA has approved a new type of stent designed specifically for infants and young children—including neonates born with congenital heart defects—that’s designed to expand in size as the ...

Ajizian held multiple positions in his more than nine years at Medtronic. In 2020, the company made Ajizian CMO of patient monitoring. Two years later, Medtronic outlined plans to spin off its ...

More than half of patients with gout from the study cohort reported experiencing peripheral neuropathy. A high prevalence of neuropathy exists among patients with gout, with key associations found ...